|
Apr 25
|
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 24
|
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
|
|
Apr 22
|
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
|
|
Apr 10
|
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
|
|
Mar 25
|
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
|
|
Mar 24
|
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint
|
|
Mar 15
|
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
|
|
Mar 13
|
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
|
|
Mar 13
|
Q4 2023 BioXcel Therapeutics Inc Earnings Call
|
|
Mar 12
|
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
|
|
Mar 7
|
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
|
|
Nov 30
|
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
|
|
Oct 31
|
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
|
|
Oct 30
|
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services
|
|
Oct 4
|
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
|